Pharmaceutical preparations containing globotetraosylceramide, globotriaozylceramide or globotetraos, and the use of said preparations or compounds for treatment, prophylaxis or diagnosis of bacterial infections in the urinary tract. The compounds have the ability to inhibit the adherence of bacteria to human urinary tract epithelial cells.
A composition suitable for topical application to human skin comprises, in addition to a suitable vehicle and a perfume, an active ingredient which can control skin barrier functions. The active ingredient is (a) a long chain .omega.-hydroxy fatty acid or a carboxy-substituted derivative, (b) an hydroxy- or epoxy-derivative of an essential fatty acid or an ester formed between (a) and (b). Certain novel compounds of structures (a), (b) and (a)(b) esters are also claimed.
The subject invention involves pharmaceutical compositions comprising a sulfated glyceroglucolipid having the structure: ##STR1## wherein n is an integer of from 1 to about 5, R is hydrogen or C.sub.1 -C.sub.24 acyl or alkyl, R' is hydrogen or C.sub.1 -C.sub.24 acyl or alkyl, and M.sup.+ is a cationic moiety, and methods of treating or preventing gastroduodenal diseases or disorders caused by or associated with H. pylori by administering such compounds.
5202357 - Skin treatment composition - Owned by Lever Brothers Company, Division of Conopco, Inc. (New York, NY) [*] Notice:The portion of the term of this patent subsequent to August 21, 2007 has been disclaimed.
A composition suitable for topical application to human skin comprises, in addition to a suitable vehicle an active ingredient which can control skin barrier functions. The active ingredient is (a) a long chain .omega.-hydroxy fatty acid or a carboxy-substituted derivative, (b) an hydroxy- or epoxy-derivative of an essential fatty acid or an ester formed between (a) and (b). Certain novel compounds of structures (a), (b) and (a)(b) esters are also claimed.
A composition suitable for topical application to human skin comprises, in addition to a suitable vehicle an active ingredient which can control skin barrier functions. The active ingredient is (a) a long chain .omega.-hydroxy fatty acid or a carboxy-substituted derivative, (b) an hydroxy-or epoxy-derivative of an essential fatty acid or an ester formed between (a) and (b). Certain novel compounds of structures (a), (b) and (a)(b) esters are also claimed.
A novel mono-sialo ganglioside derivative substantially identical chemically and physically with a product prepared by (a) concentration of an aqueous solution of a mono-sialo ganglioside and calcium ions under sub-atmospheric pressure at 40.degree.-80.degree. C. for 18-240 hours, (b) adjustment of the pH to 2-3, followed by dialysis, and (c) evaporation of the aqueous solvent. The novel ganglioside is believed to be a new physical form of the known ganglioside G.sub.M1 and shows activity against bacteria, viruses, protozoal, fungi and tumors. It has previously been suggested that gangliosides in general may be useful in the treatment of neurological disorders but not that they affect the activity of phagocytes.
